The concern is that if you overstimulate melanocytes, particularly in someone who has an underlying tendency to skin cancer, you could increase the risk of melanoma developing. In addition, melanotan II often goes along with other risky sun-seeking behaviour such as sunbed usage, Dr Wedgeworth says
[10] [12] These interactions are supported by pharmacokinetic studies, clinical observations, and drug interaction databases
Romano G, Moretti G, Di Benedetto A, et al
By contrast, the former explanation would require that we make assumptions beyond what we already know to be truei.e., that semaglutide has previously unknown impacts on CV health that are independent of its metabolic effects
These effects are typically dose-related and diminish over the first 4-8 weeks of treatment